243 results about "Hepatitis" patented technology

Provided are a double-gap modified oligonucleotide and the use thereof in resisting hepatitis B viruses and hepatitis D viruses. In particular, provided is a compound, or pharmaceutically acceptable salts, hydrates or solvates thereof, wherein (a) the compound is a double-gap modified oligonucleotide, the oligonucleotide having a sequence as shown in SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5; (b) the double-gap modification refers to that each nucleoside portion in the oligonucleotide is modified in the manner as shown in formula (I); and (c) internucleoside linkages of the oligonucleotide are unmodified or modified internucleoside linkages. The double-gap modified oligonucleotide has remarkably improved antiviral activity. Pl＞SI-P2-S2-P3 (I)

The invention belongs to the technical field of biology, and particularly relates to a mouse hepatitis virus antibody or an antigen binding fragment thereof as well as a preparation method and application thereof. The antibody or the antigen binding fragment thereof can specifically recognize and bind to the mouse hepatitis virus or the NSP3 protein thereof, and has good affinity with the mouse hepatitis virus or the NSP3 protein thereof; the kit can be used for preparing products for diagnosing, preventing and / or treating mouse hepatitis virus infection or diseases caused by the mouse hepatitis virus infection, detecting existence or level of mouse hepatitis virus or NSP3 protein in a sample, screening medicines for preventing and / or treating the mouse hepatitis virus infection or the diseases caused by the mouse hepatitis virus infection, and carrying out basic research and / or vaccine development.

The invention discloses an application of a biomarker in preparation of a kit for a prognosis risk early warning method of an acute ST segment elevation type myocardial infarction patient. The biomarker comprises an HBP (Hepatitis Binding Protein). By monitoring the change of the HBP protein level, whether a patient suffering from the acute ST segment elevation type myocardial infarction has poor prognosis within 30 days after a PCI operation can be effectively evaluated, so that early recognition and timely clinical intervention on high-risk patients are realized, the treatment response speed and effect are improved, the occurrence rate of adverse cardiovascular events is reduced, and the treatment effect of the patient suffering from the acute ST segment elevation type myocardial infarction is improved. And the prognosis of the patient is finally improved.

The invention relates to the technical field of hepatitis diagnosis and treatment management, and discloses a block chain-based hepatitis patient full-period management method. The method comprises the following steps: creating a patient identity chain in a block chain network, and storing patient registration data and initial diagnosis information; full-cycle diagnosis and treatment data of a patient are obtained and divided into clinical examination, iconography, medication records and life sign monitoring data. Performing multi-dimensional cleaning on the clinical examination data to generate a standardized data set; inputting the iconography data into a pre-trained hepatitis feature extraction model, and outputting a liver injury feature set; verifying the integrity of the medication record, and generating a non-tampering medication time sequence chain; comparing the life sign monitoring data with preset health reference parameters to generate a sign deviation coefficient set; according to the method, data safety and traceability are guaranteed through the block chain, diagnosis and treatment data quality is improved through multi-dimensional data processing, patient privacy is protected, and reliable support is provided for full-period management of hepatitis patients.

The present invention discloses the application of a molecular marker methylation level detection reagent for primary hepatocellular carcinoma in the preparation of a detection reagent product, and belongs to the field of gene detection technology. By screening the methylation level of the CpG site in the detected region and its reverse complementary sequence, it is identified whether the target sample is from a primary hepatocellular carcinoma patient. The methylation level of the CpG site in the above region has good sensitivity and specificity for the screening or auxiliary diagnosis of primary hepatocellular carcinoma, and can be used to distinguish samples from patients with primary hepatocellular carcinoma, samples from patients with benign liver diseases (cirrhosis, hepatitis, etc.) and samples from healthy people. The detection reagent and application of the methylation level of the molecular marker can improve the detection rate of early primary hepatocellular carcinoma.

The invention discloses a CRISPR / Cas12a-RPA (clustered regularly interspaced short palindromic repeats / CRISPR associated protein 12a-recombinase polymerase amplification)-based sequence combination for rapidly detecting mouse hepatitis virus and a kit thereof, and belongs to the technical field of biological detection The sequence combination comprises an RPA primer pair sequence, a crRNA sequence and an ssDNA probe sequence; the kit comprises an RPA primer pair sequence, a crRNA sequence and an ssDNA probe sequence, the kit further comprises a mouse hepatitis virus negative control standard substance, RNase-free water, an RPA reaction buffer solution, an NEB buffer solution, Lba Cas12a nuclease, dry powder RPA reaction microspheres containing recombinase polymerase and magnesium acetate with the concentration of 280 mM. The kit can be used for rapidly detecting the mouse hepatitis virus. The primer sequence combination provided by the invention is good in conservative property and specificity and relatively high in sensitivity, and rapid detection of the mouse hepatitis virus can be realized.

The invention provides an application of a compound Aldometanib in preparation of a medicine for preventing and treating immune-related adverse reactions and diseases. Based on the first discovered prevention and treatment effects of Aldometanib on fatal immune hepatitis, immune myocarditis, pneumonia and enteritis, the invention specifically discloses application of Aldometanib in preparation of drugs for prevention and treatment of immune-related adverse reactions and diseases, and the main mechanism is that Aldometanib activates immune cells AMPK, enhances catabolism of immune cells, promotes immune cell apoptosis, promotes immune cell apoptosis, and improves immune cell apoptosis. The anabolism of the immune cells is inhibited, so that the expression of effector factors of the immune cells is controlled, and inflammatory factor storm is inhibited. Aldometanib has the effects of preventing the occurrence of immune-related adverse reactions and diseases, and inhibiting the attack levels of the immune-related adverse reactions and diseases, so that non-lethal and lethal injuries caused by an immune system to body organs are reduced.

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

The invention discloses a quantitative index determination method and device based on a hepatitis pathology image, equipment, a medium and a product, and relates to the field of medical pathology image artificial intelligence analysis, and the method comprises the steps: obtaining an image of a liver puncture pathology section; according to the image of the hepatic puncture pathological section, performing feature extraction by using a multi-stage model cascade architecture to obtain a pathological feature result; the multi-stage model cascade architecture comprises an improved VM-UNet segmentation model and a VM classification model based on FEM enhancement, and the VM classification model is connected with the improved VM-UNet segmentation model; the pathological feature result comprises the expansion level of the manifold area, the necrosis type of the manifold area and the inflammatory cell information of the manifold area; and calculating a quantitative index according to the pathological feature result. According to the invention, the accuracy, objectivity, consistency and repeatability of identification can be improved.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The invention provides a probe library for high-throughput detection of mouse and hamster related species-specific viruses in a CHO cell library and application of the probe library. The probe library is used for detecting a mouse pox virus, a hantavirus, a K virus, a lactic dehydrogenase virus, a lymphocytic choriomeningitis virus, a mouse microvirus, a mouse adenovirus, a mouse cytomegalovirus, a mouse encephalomyelitis virus, a mouse hepatitis virus, a mouse rotavirus, a mouse pneumovirus, a multiple oma virus, a reovirus type 3 and a sendai virus; sV5 and thymoviruses and variant viruses thereof. The high-throughput sequencing method based on the probe library can be used for distinguishing viral nucleic acid with infection risk and quickly checking whether a sample is polluted by specific live viruses or not. The detection limit reaches the level of a traditional PCR method, the capability of detecting all known variants of to-be-detected species-specific viruses is kept, 17 viruses can be detected only by implementing one detection item, and the method has the advantages of high efficiency, rapidness and high sensitivity.

Use of a compound in the treatment of liver diseases. Experimental results show that the compound has a relatively high liver-tissue-targeting property, very low toxicity to liver primary cells and high liver safety, has significant efficacy on liver diseases such as viral hepatitis (e.g., hepatitis B) and liver cancers (including primary liver cancers and metastatic liver cancers), and has relatively good physicochemical properties, metabolic stability, bioavailability and safety, thus having very good drug development prospects.

The invention discloses application of a compound in treatment of liver diseases. Experimental results show that the compound has relatively high liver tissue targeting property, very low toxicity to liver primary cells, high liver safety and obvious curative effects on liver diseases such as viral hepatitis (such as hepatitis B), liver cancer (including primary liver cancer and metastatic liver cancer) and the like; in addition, the compound also has better physicochemical properties, metabolic stability, bioavailability and safety, and has a very good drug development prospect.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.

The invention discloses an application of TFPI2 in preparation of an anti-hepatitis B virus drug. Through in-depth study, it is found for the first time that overexpressed TFPI2 can significantly inhibit the replication ability of HBV on the cellular level and the animal level, and the expression level of HBV DNA and HBV RNA and the secretion level of HBsAg and HBeAg are reduced. Besides, mechanism analysis finds that overexpression TFPI2 promotes degradation of hepatitis B virus X protein (HBx), the half-life period of the HBx protein is remarkably shortened, and finally the HBV replication ability is damaged. Based on the research results, the application of the TFPI2 in chronic viral hepatitis B is provided for the first time, and candidate treatment targets and backup protein drugs are provided for clinical treatment of chronic hepatitis B patients.

The invention provides a traditional Chinese medicine compound for preventing and treating metabolism-related fatty liver diseases, a capsule and application, and relates to the field of medicines. The traditional Chinese medicine compound is prepared from the following raw materials in parts by weight: 1-5 parts of a turmeric extract, 10-20 parts of a radix puerariae extract, 15-30 parts of a salvia miltiorrhiza extract, 1-10 parts of a schisandra chinensis extract and 2-15 parts of a lucid ganoderma extract. The preparation method of the capsule comprises the following steps: uniformly mixing the turmeric extract, the kudzuvine root extract, the salvia miltiorrhiza extract, the schisandra chinensis extract, the lucid ganoderma extract and the maltodextrin, and filling the mixture into a hydroxypropyl methylcellulose hollow capsule to obtain the capsule. Salvia miltiorrhiza is used as a monarch drug, turmeric and radix puerariae are used as ministerial drugs, and schisandra chinensis and lucid ganoderma are used as adjuvant drugs, so that the traditional Chinese medicine composition has the functions of protecting liver, promoting blood circulation and qi circulation, helping produce saliva and slake thirst, tonifying qi and soothing nerves and the like, can effectively prevent and treat metabolism-related fatty liver diseases, and can treat non-alcoholic fatty liver diseases; particularly, the traditional Chinese medicine composition has an obvious treatment effect on non-alcoholic simple fatty liver and non-alcoholic fatty liver hepatitis.

The invention discloses a method for establishing duck hepatitis virus antibody ELISA (enzyme-linked immuno sorbent assay) detection, which comprises the following steps: firstly, preparing experimental materials, and then cloning and antigenicity analysis of structural genes, inducible expression of positive recombinants in escherichia coli, expression and purification of recombinant proteins, antigenicity analysis of the recombinant proteins and establishment of a recombinant antigen VP3 indirect ELISA method. Finally, VP0, VP3 and VP1 recombinant proteins can react with duck anti-DHV-1 positive serum and have good antigenicity, indirect ELISA results show that under the same coating concentration, the P / N value of the fusion protein GST-VP3 serving as a coating antigen is higher than that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen, it is indicated that the antigenicity of the fusion protein GST-VP3 is better than that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein GST-VP3 serving as the coating antigen and that of the fusion protein and the result is consistent with the prediction result.

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The present application relates to derivatives of STOPS™ antiviral compounds having enhanced helicity, wherein the compounds are S-antigen transport inhibiting oligonucleotide polymers. This application further relates to processes for making the compounds and methods of using them to treat diseases and conditions. In some embodiments, the diseases and conditions are related to hepatitis B and / or hepatitis D.

The invention discloses a near-infrared fluorescent probe for detecting glutathione and / or ferrous ions, and the structure of the near-infrared fluorescent probe is shown as a formula I. The near-infrared fluorescent probe disclosed by the invention is obvious in spectrum change, large in Stokes shift, high in sensitivity, strong in specificity, not easy to be interfered by biological matrixes and impurities, good in imaging effect, relatively low in cytotoxicity and relatively good in biocompatibility, and is suitable for detecting GSH and ferroptosis processes in cells and biological tissues. The invention also discloses application of the near-infrared fluorescent probe in preparation of a reagent for detecting glutathione and / or ferrous ions. The invention further discloses application of the near-infrared fluorescent probe in preparation of a kit for diagnosing hepatitis, liver injury, Parkinson's disease, Alzheimer's disease and cancer or application of the near-infrared fluorescent probe in preparation of a kit for detecting cell ferroptosis. The invention also discloses application of the near-infrared fluorescent probe in preparation of an optical imaging contrast agent. # imgabs0 #

The invention provides a nano-phase penthorum chinense pursh extract, which is prepared by the following steps: soaking a penthorum chinense pursh medicinal material, decocting, filtering, collecting filtrate, carrying out layering centrifugation to remove precipitate, dialyzing supernate by adopting a dialysis bag with the molecular weight cutoff of 3.5 kDa, and freeze-drying dialysate to obtain the nano-phase penthorum chinense pursh extract. The invention further provides a preparation method and application of the nanometer phase-state penthorum chinense pursh extract. The invention provides an extraction method capable of accurately separating 50-200nm phase-state active components in a nanometer phase-state penthorum chinense pursh extract traditional Chinese medicine. Organic solvents are prevented from being used, and the safety of extracted products is improved; the purity of the target component is improved; the structural integrity of a natural nanometer phase state is kept; the obtained nanometer phase-state extract has the effects of remarkably improving metabolic dysfunction related steatohepatitis and resisting coagulation, is high in separation efficiency, can be completed in 2-3 days, and can be applied on a large scale; the equipment is simple and low in cost.

The application discloses a tripterine self-assembled nanoparticle microsphere, a preparation method and application thereof, and belongs to the technical field of biological medicines. The tripterine self-assembled nanoparticle microsphere takes tripterine self-assembled nanoparticles as a drug core, is formed by cross-linking of a sodium alginate-pectin composite carrier through calcium ions, can significantly improve drug solubility, realizes stable protection and intestinal targeting rapid release in the gastrointestinal tract, and effectively reduces drug systemic exposure and side effect risks. The preparation process is mild and simple, the obtained preparation has high targeting and safety. Pharmacodynamic results show that the microsphere can obviously improve liver steatosis, inflammation and fibrosis related to metabolic-related fatty liver hepatitis, and has better curative effect than conventional preparations. The application provides a novel oral delivery system for preventing and treating metabolic-related fatty liver hepatitis, and has good industrial and clinical transformation prospects.

The hepatitis C detection device comprises a detection box, hepatitis C detection test paper, a blood taking needle, a hemostasis rod and an alcohol cotton ball, an observation window and a blood collection groove located below the observation window are formed in the front face of the detection box, a containing groove extending upwards is formed in one side of the bottom of the detection box, and a containing groove extending downwards is formed in the top of the detection box; the top of the detection box is covered with a cover body to form a sealed bin; the hepatitis C detection test paper is flatly laid in the detection box and corresponds to the observation window and the blood collection groove in position; a clamping ring is arranged on one side of the detection box, and the blood taking needle is embedded into the clamping ring; the hemostasis rod is inserted into the storage groove, and the end part of the hemostasis rod extends out of the storage groove; and the alcohol cotton ball is placed in the sealing bin. The blood taking needle, the hemostasis bar, the alcohol cotton ball and the like are integrated in the detection box, so that the use convenience is improved, the geographical limitation is relieved, and the detection box can be used in any occasion and is convenient and efficient.

The invention discloses a method for predicting the survival state of duck against hepatitis A virus infection. The method comprises the following steps: (1) constructing a PCA (Principal Component Analysis) prediction model by taking the contents of IFN-alpha and IFN-beta of duck blood as variables; (2) measuring the contents of IFN-alpha and IFN-beta in the duck blood to be measured; and (3) substituting the measured contents of IFN-alpha and IFN-beta in the duck blood into the prediction model, and predicting the anti-hepatitis A virus infection survival state of the duck to be detected according to the family background of the individual in combination with the output result of the prediction model. According to the method, ROC curves and corresponding AUC values of different prediction models in the aspect of predicting the survival state are compared, and the result shows that the AUC value of the PCA prediction model is the highest, and the sensitivity and the specificity are most prominent. Based on the prediction model provided by the invention, the Beijing duck individuals or strains with strong disease resistance can be rapidly screened, and the prediction model has an application prospect in duck disease resistance breeding or duck virus hepatitis prevention.

The present invention provides gene therapies for the treatment of Friedreich's ataxia. Specifically, the present invention provides a nucleic acid, cloning vector and transfer vector for the production of an adeno-associated virus (AAV) vector. The nucleic acid comprises (i) a nucleic acid sequence encoding frataxin, (ii) a phospho-glycerate-kinase (PGK) promoter, and (iii) a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The present invention also provides a pharmaceutical composition which comprises the AAV vector or nucleic acid. Also, the AAV vector, nucleic acid or pharmaceutical composition can be used as a medicament, specifically as a medicament for the treatment of Friedreich's ataxia.

To provide a diagnosis marker for a non-alcoholic fat liver disease.SOLUTION: The present invention relates to a composition and a kit for accurately diagnosing hepatitis (Non-alcoholic steatohepatitis;NASH) by including a formulation for measuring the level of ApoA-1 (Exosomal ApoA-1) protein derived from exosome, and relates to a composition and a kit for accurately predicting the prognosis after a medicine for treating non-alcoholic fat hepatitis is provided.SELECTED DRAWING: Figure 10

The invention discloses application of indole-3-propionic acid in preparation of a medicine for preventing or treating hematogenous infection, and belongs to the technical field of biological medicine. The invention discloses the application of indole-3-propionic acid in resisting blood-borne infection for the first time, the capability of capturing blood-borne pathogenic bacteria by liver Kupu cells can be remarkably enhanced by giving indole-3-propionic acid, and the load of pathogenic bacteria in circulating blood is reduced. The invention provides a new thought for treatment of hematogenous infection, especially anti-infection treatment of susceptible people with severe hepatitis or liver cirrhosis and the like. Indole-3-propionic acid is low in price and easy to obtain, can be produced in a large scale, is favorable for being developed into a medicine for treating hematogenous infection, and has a good application value.

The present invention belongs to the field of biomedical technology and provides an application of betulinone and its analogs in the prevention and treatment of fatty liver disease and adjuvant lipid-lowering. The present invention also provides a composition for treating fatty liver disease or adjuvant lipid-lowering, which comprises an effective dose of betulinone and its analogs. The betulinone and its analogs provided by the present invention have the effects of reducing blood triglyceride and liver triglyceride in vivo, reversing liver steatosis, and can improve liver fibrosis and inflammatory symptoms of mice with fatty hepatitis, and have good safety and no toxic side effects, and can be used for preparing preventive and therapeutic drugs for fatty liver disease, fatty hepatitis and related diseases.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The invention provides an intrahepatic cholangiocarcinoma organ culture medium and a culture method. The culture medium is prepared from the following components according to final concentration: 0.5 to 200 mu M of A83-01, 0.1 to 100 mu M of EGF (Epidermal Growth Factor), 10 to 500 ng / ml of FGF10 (Fibroblast Growth Factor), 1 to 200 ng / ml of HGF (Hepatitis Growth Factor), 0.5 to 200 mu M of Forskolin, 0.01 to 20 mu M of Gastrin I, 0.5 to 100 mM of Nicotinamide, 1 to 500 mu M of Y-27632, 0.5 to 100 nM of dexamethasone and 20 to 500 mu g / ml of primary cell antibiotics. All the components are dissolved in a DMEM / F12 culture solution. When the culture medium is used for culturing the intrahepatic cholangiocellular carcinoma organoid, the rapid amplification of the intrahepatic cholangiocellular carcinoma stem cells and the maturation and differentiation of the organoid are facilitated, the passage times are obviously increased, and the same tissue structure and genome characteristics of primary tissues can still be maintained after multiple passages.